SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Cemiplimab
Related studies linked through entity extraction aliases.
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
- Status
- RECRUITING
- Phase
- PHASE1
LAG3 PET Imaging in Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
- Status
- COMPLETED
- Phase
- PHASE2
Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
- Status
- UNKNOWN
- Phase
- PHASE1
Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Cemiplimab in AlloSCT/SOT Recipients With CSCC
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE2
Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2